Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry
- PMID: 35921198
- DOI: 10.1002/acr.24994
Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract
Objective: Children with well-controlled juvenile idiopathic arthritis (JIA) frequently experience flares after medication discontinuation, but the outcomes of these flares have not been well described. The objective of this study was to characterize the rates and predictors of disease recapture among children with JIA who restarted medication to treat disease flare.
Methods: Children with JIA who discontinued conventional synthetic or biologic disease-modifying antirheumatic drugs for well-controlled disease but subsequently experienced a flare and restarted medication were identified from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. The primary outcome was inactive disease (ID) (physician global assessment <1 and active joint count = 0) 6 months after flare.
Results: A total of 333 patients had complete data for ID at 6 months after flare. The recapture rate for the cohort was 55%, ranging from 47% (persistent oligoarthritis) to 69% (systemic arthritis) (P = 0.4). Approximately 67% of children achieved ID by 12 months. In the multivariable model, history and reinitiation of biologic drugs were associated with increased odds of successful recapture (odds ratio [OR] 4.79 [95% confidence interval (95% CI) 1.22-18.78] and OR 2.74 [95% CI 1.62-4.63], respectively). Number of joints with limited range of motion was associated with decreased odds (OR 0.83 per 1 joint increase [95% CI 0.72-0.95]).
Conclusion: Approximately half of JIA flares post-discontinuation were recaptured within 6 months, but rates of recapture varied across JIA categories. These findings inform shared decision-making for patients, families, and clinicians regarding the risks and benefits of medication discontinuation. Better understanding of biologic predictors of successful recapture in JIA are needed.
© 2022 American College of Rheumatology.
Comment in
-
To Wean or Not to Wean: That is the Question.Arthritis Care Res (Hoboken). 2023 Apr;75(4):712-714. doi: 10.1002/acr.24992. Epub 2022 Nov 9. Arthritis Care Res (Hoboken). 2023. PMID: 35929503 No abstract available.
References
REFERENCES
-
- Shoop-Worrall SJ, Verstappen SM, McDonagh JE, et al. Long-term outcomes following achievement of clinically inactive disease in juvenile idiopathic arthritis: the importance of definition. Arthritis Rheumatol 2018;70:1519-29.
-
- Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854-60.
-
- Selvaag AM, Lien G, Sorskaar D, et al. Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol 2005;32:1122-30.
-
- Nordal E, Zak M, Aalto K, et al. Ongoing disease activity and changing categories in a longterm nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:2809-18.
-
- Halyabar O, Mehta J, Ringold S, et al. Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Paediatr Drugs 2019;21:469-92.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
